SOURCE: BioProgress PLC

February 15, 2007 02:01 ET

BioProgress PLC announces Conference Presentation

Cambridgeshire -- (MARKET WIRE) -- February 15, 2007 --

For Immediate Release                                 15 February 2007

                             BioProgress plc

         BioProgress to present at 19th Annual Roth Capital

                 Partners Growth Stock Conference

London, UK, 15 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, announces that the Company will make a presentation at the 19th Annual Roth Capital Partners Growth Stock Conference, being held from February 19 - 22 in Laguna, California, USA.

For further information:
BioProgress Plc                             + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO

Buchanan Communications                     + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a vertically integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGELTM polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

                 This information is provided by RNS
       The company news service from the London Stock Exchange